Invesco Biotechnology & Genome ETF Rating $84.10 0.00 (0.00%) As of 06/12/2026 04:10 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOwnershipRatingsShort InterestBuy This Stock Invesco Biotechnology & Genome ETF Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.PBE Aggregate RatingModerate Buy 2.64Holdings in PBE have an aggregate rating of Moderate Buy based on 437 analyst ratings issued in the past year covering 25 companies (89.7% of the portfolio).PBE Aggregate Price Target$84.10High Prediction$84.10Average Prediction$84.10Low Prediction$84.10Holdings in PBE have an aggregate price target of $84.10 and a range of $84.10 to $84.10 covering 25 companies (89.7% of the portfolio).PBE Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy1 Buy rating(s)Moderate Buy19 Moderate Buy rating(s)Hold5 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Invesco Biotechnology & Genome ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 25 PBE Holdings ExportWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings6.70%ILMNIllumina$160.972.2516 of 5 stars2.33$142.13 -11.7%18Positive NewsGap Up5.76%UTHRUnited Therapeutics$545.964.2123 of 5 stars2.85$619.42 13.5%13Insider Trade4.93%BIIBBiogen$200.053.5817 of 5 stars2.55$217.26 8.6%294.74%INCYIncyte$108.532.8442 of 5 stars2.32$105.10 -3.2%224.45%GILDGilead Sciences$125.594.9212 of 5 stars2.86$156.93 25.0%29Trending NewsAnalyst Revision4.44%ALNYAlnylam Pharmaceuticals$282.854.6298 of 5 stars2.85$463.13 63.7%26Positive NewsAnalyst UpgradeGap Up4.30%AMGNAmgen$355.203.8153 of 5 stars2.48$354.12 -0.3%31Trending NewsAnalyst Forecast3.90%REGNRegeneron Pharmaceuticals$612.144.8577 of 5 stars2.70$792.65 29.5%27Positive News3.69%VCYTVeracyte$47.332.3519 of 5 stars2.56$47.57 0.5%9Positive News3.53%CPRXCatalyst Pharmaceuticals$31.363.6737 of 5 stars2.56$32.00 2.0%93.36%NBIXNeurocrine Biosciences$159.763.8519 of 5 stars2.87$187.52 17.4%233.35%TGTXTG Therapeutics$49.522.3093 of 5 stars2.71$52.50 6.0%7Gap Down3.32%RPRXRoyalty Pharma$54.874.569 of 5 stars3.00$53.71 -2.1%7Positive News3.23%CDNACareDx$22.972.0008 of 5 stars2.00$25.00 8.8%6Gap Up3.22%ARWRArrowhead Pharmaceuticals$74.522.7874 of 5 stars2.75$87.80 17.8%12Positive News3.07%BCRXBioCryst Pharmaceuticals$8.702.7002 of 5 stars2.75$20.70 137.9%12Gap Down3.04%EXELExelixis$53.133.0561 of 5 stars2.39$47.35 -10.9%23Positive News2.97%PTGXProtagonist Therapeutics$109.781.5978 of 5 stars2.88$115.21 5.0%16Positive News2.92%PTCTPTC Therapeutics$75.143.3304 of 5 stars2.71$91.36 21.6%14Positive NewsInsider Trade2.64%HALOHalozyme Therapeutics$69.504.2704 of 5 stars2.54$81.60 17.4%13Positive NewsGap Up2.50%RGENRepligen$130.593.8668 of 5 stars2.88$164.64 26.1%16Positive NewsGap Up2.41%TECHBio-Techne$54.003.7906 of 5 stars2.67$65.15 20.7%152.41%IONSIonis Pharmaceuticals$73.283.6192 of 5 stars2.90$100.90 37.7%21Positive News2.40%BMRNBioMarin Pharmaceutical$55.954.5188 of 5 stars2.75$88.67 58.5%242.39%ACADACADIA Pharmaceuticals$21.094.3133 of 5 stars2.67$31.63 50.0%15Positive News This page (NYSEARCA:PBE) was last updated on 6/15/2026 by MarketBeat.com Staff. From Our PartnersLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredIs SpaceX really worth 1.78 Trillion?With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...InvestPub | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredSpaceX is chump change compared to Elon’s $20T ‘iPhone’Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | SponsoredThe roadshow starts Monday. This stock isn't ready.The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...Behind the Markets | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invesco Biotechnology & Genome ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Invesco Biotechnology & Genome ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PBE Stock Alerts